Negamycin inhibits termination of protein synthesis directed by phage f2 RNA in vitro.
D000599:Amino Acids, Diamino / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000096:biosynthesis*; D002250:Carbon Radioisotopes; D002499:Centrifugation, Density Gradient; D003090:Coliphages / Q000187:drug effects / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli / Q000187:drug effects / Q000378:metabolism*; D006834:Hydrazines / Q000494:pharmacology; D007553:Isotope Labeling; D010443:Peptide Chain Termination, Translational / Q000187:drug effects*; D014176:Protein Biosynthesis / Q000187:drug effects*; D012328:RNA Viruses / Q000187:drug effects / Q000378:metabolism; D012329:RNA, Bacterial / Q000378:metabolism; D012367:RNA, Viral / Q000378:metabolism*; D012270:Ribosomes / Q000187:drug effects / Q000378:metabolism; D013307:Streptomycin / Q000494:pharmacology; D013997:Time Factors; D014633:Valine / Q000378:metabolism; D014764:Viral Proteins / Q000096:biosynthesis*
D000599:Amino Acids, Diamino; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002250:Carbon Radioisotopes; D006834:Hydrazines; D012329:RNA, Bacterial; D012367:RNA, Viral; D014764:Viral Proteins; D014633:Valine; D013307:Streptomycin